Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001829126-25-006318
Filing Date
2025-08-14
Accepted
2025-08-14 16:07:46
Documents
45
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q titanpharma_10q.htm   iXBRL 10-Q 541125
2 EXHIBIT 31.1 titanpharma_ex31-1.htm EX-31.1 14669
3 EXHIBIT 31.2 titanpharma_ex31-2.htm EX-31.2 14929
4 EXHIBIT 32.1 titanpharma_ex32-1.htm EX-32.1 6213
5 EXHIBIT 32.2 titanpharma_ex32-2.htm EX-32.2 6810
  Complete submission text file 0001829126-25-006318.txt   2725778

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ttnp-20250630.xsd EX-101.SCH 22799
7 XBRL CALCULATION FILE ttnp-20250630_cal.xml EX-101.CAL 25798
8 XBRL DEFINITION FILE ttnp-20250630_def.xml EX-101.DEF 67209
9 XBRL LABEL FILE ttnp-20250630_lab.xml EX-101.LAB 180372
10 XBRL PRESENTATION FILE ttnp-20250630_pre.xml EX-101.PRE 142828
47 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_10q_htm.xml XML 349385
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-13341 | Film No.: 251218924
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)